Drugs / [68Ga]P3
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT05940259 | May 2023 → Jul 2025 overdue | neoplasm | Peking University First Hospital | Recruiting | No outcome recorded |
| — | NCT05887687 | May 2023 → Jul 2025 overdue | neoplasm | Peking University First Hospital | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | [68Ga]P3 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05887687 ↗ |
| Modality | Diagnostic / imaging agent | “68Ga-P3, a novel molecular probe of PET imaging agent” NCT05887687 ↗ |
| Route | Intravenous | “68Ga-P3 is injected intravenously with a dose of 0.06-0.08 mCi/kg.” NCT05887687 ↗ |